CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Silica Holdings (SLCA) came out with quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.64 per share a year ago.
Oil States International (OIS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Many global investors opting to participate in the Japanese stock rally are leaning into large-caps and related ETFs. They've been rewarded for that faith, as highlighted by the WisdomTree Japan Hedged Equity ETF (DXJ) returning 20.2% YTD.
When it comes to investment-grade bond funds, sometimes fixed income investors need to take a closer look at the composition of its holdings in order to assess whether it's truly investment-grade. Vanguard has three exchange-traded funds (ETFs) that live up to the investment-grade designation.
HAMDEN, Conn.--(BUSINESS WIRE)--TransAct Technologies Incorporated (Nasdaq: TACT), a global leader in software-driven technology and printing solutions for high-growth markets, announced today that it will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024, and will host a conference call and simultaneous webcast at 8:30 p.m. ET that day. Both the call and webcast are open to the general public. The conference call number is 877-704-4453; and the conference I.
lululemon (LULU) is poised for significant expansion with its focus on three key growth drivers, product innovation, guest experience and market expansion.
Roper Technologies (ROP) came out with quarterly earnings of $4.41 per share, beating the Zacks Consensus Estimate of $4.34 per share. This compares to earnings of $3.90 per share a year ago.
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST for the treatment of Stargardt disease (Phase 1/2 GARDian clinical trial) at The Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA from May 5-9, 2024.
Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.